The United Laboratories International Holdings' (HKG:3933) Liraglutide injection was approved by China's National Medical Products Administration for blood glucose control in adults with type 2 diabetes.
The drug, developed by subsidiary Zhuhai United Bio-Pharmaceutical, can be used alone or with metformin or sulfonylurea for patients needing additional control, according to a Friday filing with the Hong Kong bourse.